Meeting
2022 ASCO Annual Meeting
Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
Authors
Eileen Mary O'Reilly
Memorial Sloan Kettering Cancer Center, New York, NY
Eileen Mary O'Reilly , Talia Golan , Masafumi Ikeda , Michele Milella , Julien Taieb , Zev A. Wainberg , Li-Wei Wang , Nana Gyambibi , Eva Maria Lopez-Martin , Kun Xu , Teresa Macarulla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT04935359
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4193)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4193
Abstract #
TPS4193
Poster Bd #
161b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Zev A. Wainberg
Poster
2022 ASCO Annual Meeting
Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai
Poster
2021 ASCO Annual Meeting
Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Peter Grell